Overview
- 17 inspections across 17 sites are on record.
- 0 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-01-16.
At a glance
Inspections
17
Sites
17
Observations
0
Career since
Aug 2022
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 16 Jan 2026 | Human Drugs | On file |
| Lupin Limited | 19 Sep 2025 | Human Drugs | On file |
| GlaxoSmithKline LLC | 7 Mar 2025 | Human Drugs | On file |
| Intas Pharmaceuticals Limited | 14 Feb 2025 | Human Drugs | On file |
| CELLTRION Inc | 14 Jan 2025 | Human Drugs |
Sites inspected
Regeneron Pharmaceuticals, Inc.East Greenbush, United States1 insp.
Lupin LimitedPune, India1 insp.
GlaxoSmithKline LLCConshohocken, United States1 insp.
Intas Pharmaceuticals LimitedMoraiya, India1 insp.
CELLTRION IncYeonsu District, Korea (the Republic of)1 insp.
Co-investigators
Investigators who share inspections with this person.
Madushini N Dharmasena3 shared
Cassandra L Abellard2 shared
Jacek Cieslak2 shared
Jiangsong Jiang1 shared
Prabuddha Sengupta1 shared
Shadia Zaman1 shared
Karthik M Krishnan1 shared
Olumide A Martins1 shared
Bingchen Du1 shared
Doan N Singh1 shared
Full investigator report
Get the verbatim findings behind Hamet M Toure's inspection record
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site